Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.65 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.64 |
| ▸ | ABL1 | P00519 | 6/20 | 0.64 |
| ▸ | INSR | P06213 | 6/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 6/20 | 0.64 |
| ▸ | CDK2 | P24941 | 6/20 | 0.64 |
| ▸ | PLK1 | P53350 | 5/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.64 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.64 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.64 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.64 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.64 |
| ▸ | HDAC7 | Q8WUI4 | 4/20 | 0.64 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.64 |
| ▸ | HDAC10 | Q969S8 | 4/20 | 0.64 |
| ▸ | HDAC11 | Q96DB2 | 4/20 | 0.64 |
| ▸ | HDAC9 | Q9UKV0 | 4/20 | 0.64 |
| ▸ | HDAC5 | Q9UQL6 | 4/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28421233 | 0.88 | EGFR (0.66) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL4090004 | 0.86 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL3799823 | 0.85 | EGFR (0.78) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL28350097 | 0.84 | EGFR (0.75) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL142106 | 0.84 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL29387336 | 0.84 | EGFR (0.79) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL2993473 | 0.84 | EGFR (0.72) | EGFRERBB2ABL1INSRPDGFRB | |
| Hydrochloric Acid SCHEMBL2511570 | 0.83 | EGFR (0.78) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL17083347 | 0.83 | EGFR (0.74) | EGFRERBB2ABL1INSRPDGFRB | |
| SCHEMBL12795405 | 0.82 | EGFR (0.66) | EGFRERBB2ABL1INSRPDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | disclosed |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | LEO OSPREY LIMITED (GB) | 2008-03-06 | — | — | US | disclosed |
| EP-1294715-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2003-03-26 | — | — | EP | disclosed |
| WO-2002002552-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885ABL1 2/4885 |
| US-20080058519-A1 | QUINAZOLINE DITOSYLATE SALT COMPOUNDS | ERBB4, ABL1, ERBB2 | EGFR 64/4885ERBB2 3/4885ABL1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.